Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial

Leukemia

Volumn 23, Issue 7, 2009, Pages 1337-1341

  Reeder, C B ^a   Reece, D E ^b   Kukreti, V ^b   Chen, C ^b   Trudel, S ^b   Hentz, J ^a   Noble, B ^a   Pirooz, N A ^a   Spong, J E ^a   Piza, J G ^b   Zepeda, V H J ^a   Mikhael, J R ^a   Leis, J F ^a   Bergsagel, P L ^a   Fonseca, R ^a   Stewart, A K ^a  

^a MAYO CLINIC   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFUSION; CYSTITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; GENE DELETION; GENETIC RISK; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; MALE; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 67650882695     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.26     Document Type: Article

References (33)

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy M, Hayman S, Buadi F et al Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
2. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158-164.
3. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer E, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
5. Weber D. Thalidomide and its derivatives: New promise for multiple myeloma. Cancer Control 2003; 10: 375-383.
6. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
7. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer S, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (REV/ DEX) for newly diagnosed myeloma. Blood 2005; 106: 4050-4053.
8. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
9. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos M, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
10. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomized controlled trial. Lancet 2006; 367 825-831.
11. Wang M, Weber DM, Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 2005; 79: 194-197.
12. Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008; 112: 3115-3121.
13. Lacy MQ, Gertz MA, Dispenzieri A, Hayman S, Geyer S, Kabat B et al Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007; 82: 1179-1184.
14. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776-783.
15. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): A novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003; 10: 361-369.
16. Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007; 12: 235-239.
17. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M et al. Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3. Br J Haematol 2007; 138: 176-185.
18. Trieu Y, Trudel S, Pond GR, Mikhael J, Jaksic W, Reece D et al. Weekly cyclophosphamide and alternate-day prednisone: An effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc 2005; 80: 1578-1582.
19. Reece DE, Piza Rodriguez G, Chen C, Trudel S, Kukreti V, Mikhael J et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008; 26: 4777-4783.
20. Blade J, Sampson D, Reece D, Apperley J, BJOrkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
21. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
22. Rajkumar SV, Durie BG. Eliminating the complete response penalty from myeloma response criteria. Blood 2008; 111: 5759-5760.
23. Greipp PR, San Miguel J, Durie BG, Crowley J, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
24. Prince HM, Imrie K, Sutherland DR, Keating A, Meharchand J, Crump RM et al. Peripheral blood progenitor cell collections in multiple myeloma: Predictors and management of inadequate collections. Br J Haematol 1996; 93: 142-145.
25. Gertz MA, Lacy MQ, Inwards DJ, Pineda A, Chen M, Gastineau D et al Factors influencing platelet recovery after blood cell transplantation in multiple myeloma. Bone Marrow Transplant 1997; 20: 375-380.
26. Kumar S, Dispenzieri A, Lacy MQ, Hayman S, Buadi F, Gastineau D et al Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035-2042.
27. Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda V, Pirooz N et al Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008; 22: 1282-1284.
28. Attal M, Harousseau JL. Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol Clin North Am 1997; 11: 133-146.
29. Child JA, Morgan GJ, Davies FE, Owen R, Bell S, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
30. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen F, Fuzibet J-G et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
31. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289-3294.
32. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F et al Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434-2441.
33. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized, controlled trial. Blood 2008; 112: 3107-3114.